Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving innovations at risk.

Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

Popular global HIV/AIDS program PEPFAR has been spared as Congress passes a package with billions of dollars in spending cuts ...

Newsday Zimbabwe HEALTH and Child Care minister Douglas Mombeshora has reaffirmed the country’s commitment to advancing HIV research, treatment and global collaboration. He said this during the ...

PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

The International AIDS Society (IAS) has praised a bipartisan effort by the United States Senate to shield the President’s ...